Company: SMNR
Filing Date: 2025-08-15
Form Type: 10-Q
Source: 0001213900-25-077047
Chunk: 4

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-08-15
Form: 10-Q
Item: Part I, Item 1
Chunk 4
---
 448,912 
  
    Subsequent measurement of ordinary shares subject to possible redemption (interest earned on trust account and extension deposit) 
     -  
     -  
     -  
     -  
     (790,157) 
     (790,157)
  
    Balance as of June 30, 2024 (Unaudited) 
     510,000  
    $51  
    $2,062,500  
    $206  
    $(9,163,097) 
    $(9,162,840)

The accompanying notes are an integral part of these unaudited
condensed consolidated financial statements.

3

DENALI CAPITAL ACQUISITION CORP.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

    For the  Six Months  
    For the  Six Months 

    Ended  
    Ended 

    June 30, 2025  
    June 30, 2024 
  
    Cash flows from operating activities: 

    Net (loss) income 
    $(579,725) 
    $713,242 
  
    Adjustments to reconcile net (loss) income to net cash used in operating activities: 

    Income from Trust 
     (97,051) 
     (1,294,042)
  
    Changes in current assets and liabilities: 

    Prepaid Expenses 
     (14,018) 
     (37,307)
  
    Accounts payable and accrued expenses 
     451,962  
     85,080 
  
    Accrued interest expense -related party 
     35,682  
     24,617 
  
    Accrued interest expense - others 
     19,638  
     19,746 
  
    Net cash used in operating activities 
     (183,512) 
     (488,664)

    Cash flows from investing activities: 

    Cash withdrawn from Trust Account in connection with redemption 
     8,617,553  
     - 
  
    Net cash generated by investing activities 
     8,617,553  
     - 

    Cash flows from financing activities: 

    Proceeds from issuance of promissory note to related party 
     166,770  
     285,700 
  
    Redemption of ordinary shares